Exavir Therapeutics was founded in late 2020 with co-founders Alborz Yazdi, Howard Gendelman, and Benson Edagwa to advance the mission of developing ultra-long-acting therapeutics for patients living with chronic disorders. Dr. Gendelman and Dr. Edagwa have been conducting research on macrophage depots for long-acting injectables for nearly 20 years at the University of Nebraska Medical Center.